Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33785876/
doi: 10.1038/s41416-021-01362-5. Online ahead of print. 1 Department of Cell Biology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou, China. 2 Department of Ophthalmology, The Second Affiliated Hospital...
-
Mark Fesler5yrThis may be the first study defining the importance of this protein ITGA6 in myeloma. An interesting inverse correlation with disease aggressiveness ...
Role of FDG PET in the staging of multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33813607/
18 F-Fluorodeoxyglucose (FDG) PET has been used for staging of hematologic malignancies for years. In multiple myeloma, this imaging modality can be used in many different scenarios, including initial staging,...
-
Mark Fesler5yrA nice comprehensive review of pet in plasma cell dyscrasias. Overall this modality has taken on an increasing important role in the care of these patients in the last Show More
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33822368/
doi: 10.1111/bjh.17435. Online ahead of print. 1 Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 2 National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 3 Institut...
-
Mark Fesler5yrThis research is consistent with many other HRQOL studies by showing that this parameter is improved in patients with better disease control
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33814336/
Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend...
-
Mark Fesler5yrDeath within a year of autoSCT not only indicates a disease resistant to chemo but also novel agents given the prolonged pfs of triplet regimens in salvage. These patients Show More
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33682447/
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates...
-
Mark Fesler5yrThis antibody conjugate has intriguing efficacy in a population of patients that has few options ...